Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation

Satish Shanbhag1,2, Mitchell R Smith1, Robert VB Emmons21Department of Medical Oncology, Fox Chase Cancer Center, 2Division of Bone Marrow Transplantation, Temple University, Philadelphia, PA, USAAbstract: Mantle cell lymphoma (MCL) is a type of non-Hodgkins lymphoma (NHL) associated with poor progr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Satish Shanbhag, Mitchell R Smith, Robert VB Emmons
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Cytology QH573-671
Acceso en línea:	https://doaj.org/article/d68f3bca3b8a4460ae9101b261536de9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d68f3bca3b8a4460ae9101b261536de9
record_format	dspace
spelling	oai:doaj.org-article:d68f3bca3b8a4460ae9101b261536de92021-12-02T03:30:36ZTackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation1178-6957https://doaj.org/article/d68f3bca3b8a4460ae9101b261536de92010-07-01T00:00:00Zhttp://www.dovepress.com/tackling-mantle-cell-lymphoma-mcl-potential-benefit-of-allogeneic-stem-a4785https://doaj.org/toc/1178-6957Satish Shanbhag1,2, Mitchell R Smith1, Robert VB Emmons21Department of Medical Oncology, Fox Chase Cancer Center, 2Division of Bone Marrow Transplantation, Temple University, Philadelphia, PA, USAAbstract: Mantle cell lymphoma (MCL) is a type of non-Hodgkins lymphoma (NHL) associated with poor progression-free and overall survival. There is a high relapse rate with conventional cytotoxic chemotherapy. Intensive combination chemotherapy including rituximab, dose intense CHOP- (cyclophosphamide-doxorubicin-vincristine-prednisone) like regimens, high dose cytarabine, and/or consolidation with autologous stem cell transplant (autoSCT) have shown promise in significantly prolonging remissions. Data from phase II studies show that even in patients with chemotherapy refractory MCL, allogeneic stem cell transplant (alloSCT) can lead to long term disease control. Most patients with MCL are not candidates for myeloablative alloSCT due to their age, comorbidities, and performance status. The advent of less toxic reduced intensity conditioning (RIC) regimens, which rely more on the graft-versus-lymphoma (GVL) effect, have expanded the population of patients who would be eligible for alloSCT. RIC regimens alter the balance of toxicity and efficacy favoring its use. Treatment decisions are complicated by introduction of novel agents which are attractive options for older, frail patients. Further studies are needed to determine the role and timing of alloSCT in MCL. Currently, for selected fit patients with chemotherapy resistant MCL or those who progress after autoSCT, alloSCT may provide long term survival.Keywords: mantle cell lymphoma, allogeneic SCT, nonmyeloablative, GVL Satish ShanbhagMitchell R SmithRobert VB EmmonsDove Medical PressarticleCytologyQH573-671ENStem Cells and Cloning: Advances and Applications, Vol 2010, Iss default, Pp 93-102 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cytology QH573-671
spellingShingle	Cytology QH573-671 Satish Shanbhag Mitchell R Smith Robert VB Emmons Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation
description	Satish Shanbhag1,2, Mitchell R Smith1, Robert VB Emmons21Department of Medical Oncology, Fox Chase Cancer Center, 2Division of Bone Marrow Transplantation, Temple University, Philadelphia, PA, USAAbstract: Mantle cell lymphoma (MCL) is a type of non-Hodgkins lymphoma (NHL) associated with poor progression-free and overall survival. There is a high relapse rate with conventional cytotoxic chemotherapy. Intensive combination chemotherapy including rituximab, dose intense CHOP- (cyclophosphamide-doxorubicin-vincristine-prednisone) like regimens, high dose cytarabine, and/or consolidation with autologous stem cell transplant (autoSCT) have shown promise in significantly prolonging remissions. Data from phase II studies show that even in patients with chemotherapy refractory MCL, allogeneic stem cell transplant (alloSCT) can lead to long term disease control. Most patients with MCL are not candidates for myeloablative alloSCT due to their age, comorbidities, and performance status. The advent of less toxic reduced intensity conditioning (RIC) regimens, which rely more on the graft-versus-lymphoma (GVL) effect, have expanded the population of patients who would be eligible for alloSCT. RIC regimens alter the balance of toxicity and efficacy favoring its use. Treatment decisions are complicated by introduction of novel agents which are attractive options for older, frail patients. Further studies are needed to determine the role and timing of alloSCT in MCL. Currently, for selected fit patients with chemotherapy resistant MCL or those who progress after autoSCT, alloSCT may provide long term survival.Keywords: mantle cell lymphoma, allogeneic SCT, nonmyeloablative, GVL
format	article
author	Satish Shanbhag Mitchell R Smith Robert VB Emmons
author_facet	Satish Shanbhag Mitchell R Smith Robert VB Emmons
author_sort	Satish Shanbhag
title	Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation
title_short	Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation
title_full	Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation
title_fullStr	Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation
title_full_unstemmed	Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation
title_sort	tackling mantle cell lymphoma (mcl): potential benefit of allogeneic stem cell transplantation
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/d68f3bca3b8a4460ae9101b261536de9
work_keys_str_mv	AT satishshanbhag tacklingmantlecelllymphomamclpotentialbenefitofallogeneicstemcelltransplantation AT mitchellrsmith tacklingmantlecelllymphomamclpotentialbenefitofallogeneicstemcelltransplantation AT robertvbemmons tacklingmantlecelllymphomamclpotentialbenefitofallogeneicstemcelltransplantation
_version_	1718401762014003200

Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation

Ejemplares similares